Skip to main content
Retour
ABVX logo

Abivax S.A.

Qualité des données : 100%
ABVX
NASDAQ Healthcare Biotechnology
115,42 €
▼ 4,92 € (-4,09%)
Cap. Boursière : 7,57B
Également cotée sous AAVXF OTC
Fourchette du Jour
115,02 € 122,97 €
Fourchette 52 Semaines
4,77 € 148,83 €
Volume
1 265 517
Moyenne 50J / 200J
119,11 € / 87,46 €
Clôture Précédente
120,34 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -42,9 0,4
P/B 186,5 2,9
ROE % -149,0 3,8
Net Margin % -1633,1 3,9
Rev Growth 5Y % 261,8 10,0
D/E 2,4 0,2

Objectif de Cours des Analystes

Hold
142,50 € +23.5%
Low: 110,00 € High: 176,00 €
BPA Prévisionnel
-3,07 €
CA Est.
3,8 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 4,96 €
3,05 € – 6,87 €
1,5 B 1
FY2029 5,35 €
3,29 € – 7,41 €
1,2 B 1
FY2028 0,71 €
0,31 € – 1,11 €
570 M 2

Points Clés

Revenue grew 261,78% annually over 5 years — strong growth
Debt/Equity of 2,40 — high leverage
Negative free cash flow of -154,72M
PEG of 0,14 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 128,24%
Capital efficient — spends only 5,96% of revenue on capex

Croissance

Revenue Growth (5Y)
261,78%
Revenue (1Y)133,54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-148,98%
ROIC-94,05%
Net Margin-1633,08%
Op. Margin-1602,89%

Sécurité

Debt / Equity
2,40
Current Ratio1,84
Interest Coverage-41,33

Valorisation

P/E Ratio
-42,94
P/B Ratio186,47
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 133,54% Revenue Growth (3Y) 53,45%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 261,78% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10,79M Net Income (TTM) -176,24M
ROE -148,98% ROA -85,88%
Gross Margin 100,00% Operating Margin -1602,89%
Net Margin -1633,08% Free Cash Flow (TTM) -154,72M
ROIC -94,05% FCF Growth (3Y) N/A
Safety
Debt / Equity 2,40 Current Ratio 1,84
Interest Coverage -41,33 Dividend Yield 0,00%
Valuation
P/E Ratio -42,94 P/B Ratio 186,47
P/S Ratio 701,25 PEG Ratio 0,14
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 7,57B Enterprise Value 7,52B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 10,79M 4,62M 4,58M 37 000,0 63 000,0
Net Income -176,24M -147,74M -60,74M -42,45M -37,55M
EPS (Diluted) -2,80 -3,43 -3,18 -2,75 -2,62
Gross Profit 10,79M 4,57M 4,47M -119 000,0 -33,77M
Operating Income -172,98M -127,38M -64,84M -41,40M -38,01M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 205,23M 327,06M 75,54M 109,23M 71,30M
Total Liabilities 164,64M 131,05M 68,36M 83,30M 53,40M
Shareholders' Equity 40,58M 196,01M 7,19M 25,93M 17,90M
Total Debt 97,36M 58,04M 39,16M 51,65M 33,99M
Cash & Equivalents 144,22M 251,94M 26,95M 60,70M 29,30M
Current Assets 170,67M 285,97M 36,18M 75,21M 37,67M
Current Liabilities 92,83M 88,12M 51,46M 32,26M 19,41M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#5 of 146
77

Activité Récente

Entré Full Throttle
Mar 24, 2026